Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

21 May 2009

Generic Formulations of Immunosuppressive. Is it always safe to swith?

D W Holt

Ann Transplant 2009; 14(1): 11-11 :: ID: 880236


Immunosuppressive drugs are critical dose drugs - small changes in the dose
or systemic exposure can result in changes in both their efficacy and toxicity. The primary immunosuppressive drugs in use today, ciclosporin and tacrolimus, are now available as generic formulations. There are international criteria for testing generic formulations against the innovator drug, designed to guarantee the bioequivalence of the two formulations. Whilst there are many excellent generic formulations, which allow trouble-free switching between brands of the same active drug, there are concerns regarding the criteria used to test generic formulations for indications such as transplantation. These concerns are reected by the recent introduction of more stringent criteria for critical dose drugs in Canada and Denmark, and proposed changes by the EU regulatory body. Generic formulations manufactured in some parts of the world give rise to more serious concerns, both in terms of the amount of drug they contain and the excipients in the formulations. This presentation will focus on some of the issues relating to the quality of generic medicines and the impact they could have on efficacy and toxicity following organ transplantation. It will be concluded that, whilst the use of generic formulations may hold out the prospect of cost savings, the total economic impact of brand switching should be taken into consideration.
Clinicians should be aware that a simple comparison of pharmacokinetic
properties may not necessarily equate to therapeutic equivalence.

Keywords: immunosuppressive drugs, toxicity, Organ Transplantation

Add Comment 0 Comments

In Press

12 Feb 2024 : Original article  

No Prognostic Impact of Graft-to-Recipient Weight Ratio on Hepatocellular Carcinoma Recurrence Following Li...

Ann Transplant In Press; DOI: 10.12659/AOT.942767  

21 Feb 2024 : Original article  

Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians

Ann Transplant In Press; DOI: 10.12659/AOT.943498  

Most Viewed Current Articles

05 Apr 2022 : Original article  

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

12 Jan 2022 : Original article  

Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...

DOI :10.12659/AOT.934738

Ann Transplant 2022; 27:e934738

22 Nov 2022 : Original article  

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358